Heart Cell Therapy Aims to Regrow Damaged Heart Muscle
Adults who survive severe heart attacks may eventually have a regenerative option, but the therapy has not yet been tested in patients.
Updated on Nov. 5, 2026 in Heart Disease
Live Poll
Do you think new medical treatments should be accessible to patients regardless of income?
The California Institute for Regenerative Medicine has awarded a $6.9 million grant to support preclinical development of a heart cell therapy created by USC Stem Cell scientists. The therapy is designed to regenerate heart muscle after a severe heart attack, with human clinical trials targeted to launch in late 2027 at USC and the University of Washington.
Why it matters
Patients who suffer a heart attack with cardiogenic shock face very high short-term mortality, and the heart has a very limited ability to repair itself after severe damage. A therapy that could regenerate cardiac muscle would address that gap directly, which is why the state's regenerative medicine institute is funding the work now, before human testing begins.
This is a preclinical funding award, not a clinical study, so no human efficacy data are reported. The grant supports rigorous testing, process development, manufacturing and clinical planning for a therapy that remains untested in patients.
The players
California Institute for Regenerative Medicine (CIRM)
California's state-funded agency that supports stem cell and regenerative medicine research and clinical development.
University of Southern California (USC)
Home of USC Stem Cell, the research group that created the cardiac cell therapy and a planned clinical trial site.
University of Washington
A planned clinical trial site for the heart cell therapy.
Marcus Foundation
The funder supporting the clinical trial targeted for late 2027.
Sanjeet Patel
Developer of the artificial intelligence algorithm used to identify trial participants who will benefit most.
The details
The therapy uses banked stem cells, a subset of which are developed into cardiac muscle and frozen, creating an off-the-shelf product that does not need customization for each patient. The clinical version requires immunosuppressive drugs to prevent the body from rejecting the transplanted cells. An artificial intelligence algorithm developed by Sanjeet Patel will be used to identify the trial participants most likely to benefit.
Timeline
November 5, 2026: CIRM grant announced for heart cell therapy development.
Late 2027: Targeted launch of human clinical trials to test safety and feasibility.
Health Landscape
Heart cell therapies remain experimental, and most regenerative approaches for the heart are still in early development rather than in established clinical use. This grant moves a USC-developed off-the-shelf approach toward human testing, adding one candidate to a pipeline that has not yet produced an approved cardiac regeneration treatment.
This is a research development with no near-term change to care, and the therapy is not available outside a future clinical trial. Anyone with a history of heart attack or heart failure who wants to understand what future options may exist should raise it with their cardiologist.
The takeaway
A regenerative therapy for heart muscle is moving toward human testing, but it remains unproven in patients. Anyone interested in future clinical trial options for heart damage can ask their cardiologist whether research studies are appropriate for their situation.
What happens next
Human clinical trials to test safety and feasibility are targeted to launch in late 2027 at USC and the University of Washington.
Further reading
For more on the conditions this therapy targets, explore our Heart Disease coverage.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you think new medical treatments should be accessible to patients regardless of income?
